Nurix Therapeutics, Inc.
$17.04
▲
0.19%
2026-04-21 08:28:01
www.nurixtx.com
NGM: NRIX
Explore Nurix Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.81 B
Current Price
$17.04
52W High / Low
$22.5 / $8.2
Stock P/E
—
Book Value
$4.65
Dividend Yield
—
ROCE
-47.48%
ROE
-61.4%
Face Value
—
EPS
$-3.17
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
317
Beta
1.98
Debt / Equity
12.2
Current Ratio
6.01
Quick Ratio
7.02
Forward P/E
-5.63
Price / Sales
23.09
Enterprise Value
$1.18 B
EV / EBITDA
-3.83
EV / Revenue
16.38
Rating
Strong Buy
Target Price
$30.24
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zentalis Pharmaceuticals, Inc. | $4.03 | — | $301.33 M | — | -57.45% | -49.54% | $6.95 / $1.13 | $3.13 |
| 2. | KalVista Pharmaceuticals, Inc. | $20.87 | — | $1.07 B | — | -89% | -121.5% | $21.3 / $9.83 | $-0.05 |
| 3. | Travere Therapeutics, Inc. | $40.29 | — | $3.72 B | — | -14.11% | -57.8% | $43.31 / $13.88 | $1.26 |
| 4. | Tenaya Therapeutics, Inc. | $0.74 | — | $169.71 M | — | -70.98% | -83.84% | $2.35 / $0.36 | $0.57 |
| 5. | Matinas BioPharma Holdings, Inc. | $0.55 | — | $3.52 M | — | -202.13% | -1.67% | $3.09 / $0.48 | $1.09 |
| 6. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
| 7. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|---|
| Sales | 6.25 M | 13.58 M | 7.89 M | 44.06 M | 18.45 M | — |
| Operating Profit | -92.5 M | -83.09 M | -91.39 M | -48.32 M | -62.86 M | — |
| Net Profit | -87.17 M | -78.22 M | -86.42 M | -43.46 M | -56.35 M | — |
| EPS in Rs | -0.84 | -0.76 | -0.84 | -0.42 | -0.54 | -0.75 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 83.98 M | 54.55 M | 76.99 M | 38.63 M |
| Operating Profit | -285.67 M | -213.03 M | -155.06 M | -183.87 M |
| Net Profit | -264.46 M | -193.57 M | -143.95 M | -180.36 M |
| EPS in Rs | -2.56 | -1.87 | -1.39 | -1.74 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 688.13 M | 669.34 M | 355.6 M | 416.76 M |
| Total Liabilities | 149.39 M | 142.35 M | 155.1 M | 113.06 M |
| Equity | 538.75 M | 526.99 M | 200.49 M | 303.7 M |
| Current Assets | 606.82 M | 619.39 M | 295.5 M | 318.45 M |
| Current Liabilities | 86.47 M | 95.85 M | 86.96 M | 70.66 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -249.47 M | -172.58 M | -81.36 M | -159.81 M |
| Investing CF | 147.85 M | -257.71 M | 68.3 M | 27.2 M |
| Financing CF | 238.64 M | 485.67 M | 3.22 M | 117.19 M |
| Free CF | -263.47 M | -181.86 M | -89.77 M | -172.05 M |
| Capex | -14 M | -9.27 M | -8.4 M | -12.24 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -29.15% | 99.31% | — | — |
| Earnings Growth % | -34.47% | 20.19% | — | — |
| Profit Margin % | -354.85% | -186.98% | -466.93% | — |
| Operating Margin % | -390.52% | -201.41% | -476.01% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -360.41% | -183.68% | -448.03% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.